ArticleFrontiers in medicine2024
Safety and efficacy of 48-week pegylated interferon-
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04035837 (A Study of Peg-interferon Treatment for Nucleos), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Peg-interferon Treatment for Nucleos(t)Ide Analogues Suppressed Chronic Hepatitis B Patients With Low Level Hepatitis Surface Antigen
Who cites it
8 citing papers in PubMed.
- qHBsAg Trajectories with Peg-IFNα-2b Add-on Therapy in Nucleos(t)ide Analog-experienced HBeAg-positive Chronic Hepatitis B.Journal of clinical and translational hepatology · 2026Article
- Baseline Liver Fibrosis Severity Predicts Superior HBeAg Clearance and Fibrosis Reversal following Peg-IFNα plus Nucleos(t)ide Analog Therapy in HBeAg-positive Chronic Hepatitis B Patients.Journal of clinical and translational hepatology · 2026Article
- Pegylated interferon-α-2b add-on therapy to renal function for chronic hepatitis B patients who were treated with tenofovir disoproxil fumarate: a retrospective real-world study.Virology journal · 2026Observational
- Association of week-12 HBsAg Decline with HBsAg Clearance in Patients with Hepatitis B-Related Cirrhosis Receiving Pegylated Interferon Combined with Nucleos(T)ide Analogue Therapy: A Retrospective Cohort Study.International journal of general medicine · 2026Article
- Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B.Frontiers in cellular and infection microbiology · 2026Review
- Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study.Virology journal · 2025Observational
- Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.Drug design, development and therapy · 2025Review
- Safety evaluation and toxicokinetics of repeated inhalation exposure to pegylated interferon α-2b.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pegylated interferon- Methods: This was a single-center study. Fifty-four patients with HBV-related compensated cirrhosis were enrolled. All patients received subcutaneous injection of PEG-IFN- Results: Forty-two patients achieved undetectable serum HBV DNA at 48 weeks post-therapy. HBsAg level was significantly reduced at 48 weeks post-therapy (227.2 IU/mL vs. 1,668 IU/mL; Conclusion: A finite course of PEG-IFN- Clinical trial registration: This trial is a part of ZhuFeng Project (ClinicalTrials.gov, identifier NCT04035837).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.